http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
- 中文 을 입력하시려면 zhongwen을 입력하시고 space를누르시면됩니다.
- 北京 을 입력하시려면 beijing을 입력하시고 space를 누르시면 됩니다.
RISS 인기검색어
- 검색키워드
- 저자 : ( Kathryn Kersey ) (검색결과 2 건)
- 무료
- 기관 내 무료
- 유료
-
( K Rajender Reddy ),( Marc Bourliere ),( Kosh Agarwal ),( Eric Lawitz ),( Leia Kim ),( Anu Osinusi ),( Kathryn Kersey ),( Gerald Crans ),( Stephanie Moody ),( Liyun Ni ),( Diana M. Brainard ),( John 대한간학회 2017 춘·추계 학술대회 (KASL) Vol.2017 No.1
Aims: Sustained virologic response (SVR) after interferon (IFN)-based treatment for HCV infection is associated with reduced risk of hepatocellular cancer (HCC), although the risk is not eliminated. Less is known regarding the risk of de novo HCC following SVR with IFN-free direct acting antiviral (DAA) therapy. In this analysis, a review of incident HCC in patients treated with SOF-containing regimens was performed. Methods: Data from Gilead HCV clinical trials (from treatment start to 24 weeks post-treatment) and registry studies (3 to 5 year follow-up observation) were analyzed to evaluate the incidence of de novo HCC. The clinical database was searched to identify adverse events of liver tumors; the occurrence of HCC is recorded at each visit in the registry studies. Incidence rates and exposure-adjusted incidence rates, time to development, and risk factors for development of HCC were assessed in patients with and without cirrhosis (compensated and decompensated) who received IFN- containing (Peg- IFN+RBV±SOF) vs IFN-free treatment (SOF, ledipasvir/SOF, SOF/velpatasvir ± RBV), and SVR vs no SVR. Results: In the clinical trial database, 0.3% (36 of 13,525) patients had AEs of HCC or suspected HCC while in the registry study database, 0.5% (33 of 6675) were reported to have HCC. The rate was similar in non-cirrhotic patients who achieved SVR with an IFN-containing vs IFN-free regimen (0.09 vs 0.03 per 100 patient years of follow-up, respectively); few patients with compensated cirrhosis and none with decompensated cirrhosis received IFN-containing regimens. Among subjects treated with IFN-free regimens, higher rates were observed with advanced liver disease and non SVR (see table). Conclusions: Data from the Gilead clinical trial and registry study databases show incidence of HCC in subjects treated with IFN-free regimens is similar to that reported in the IFN-era in similar populations. While SVR significantly reduces the risk of HCC, the risk is not completely eliminated, particularly among patients with decompensated cirrhosis.
-
( Harsha Pokkalla ),( Kishalve Pethia ),( Benjamin Glass ),( Jennifer Kaplan Kerner ),( Ling Han ),( Catherine Jia ),( Ryan Huss ),( Mar-ianne Camargo ),( Kathryn Kersey ),( Chuhan Chung ),( G. Mani S 대한간학회 2020 춘·추계 학술대회 (KASL) Vol.2020 No.1
Aims: Fibrosis is the primary determinant of disease progression in patients with nonalcoholic steatohepatitis (NASH), but the prognostic impact of other histological features is unclear. We used a machine learning(ML) approach to identify novel morphologic features and associations with disease progression in NASH patients with F3/4 fibrosis. Methods: Biopsies from 644 patients screened in phase3 trial of selonsertib (STELLAR-4) were scored by a central pathologist( CP) according to the NASH CRN and Ishak staging systems. The PathAI research platform(PathAI, Boston, MA) was trained a convolutional neural network(CNN) with >68,000 annotations (e.g. steatosis, ballooning, lobular/portal inflammation) collected from 75 board-certified pathologists on images of H&E and trichrome(TC) stained slides. For staging fibrosis, CNN models were trained using slide-level pathologist scores to recognize unique patterns associated with each stage within fibrotic regions of TC images. 202 features were extracted from biopsy images from patients (F3-F4) enrolled in the STELLAR trials. Cox regression was used to identify associations between these features with progression to cirrhosis in F3 patients, and liver-related events (e.g. decompensation, transplantation, death) in F4 patients. Results: 1526 NASH patients with F3-F4 fibrosis (median age 59 yrs, 73% diabetic, 52% F4) were included. During a median follow-up of 16.5 mos, 14.5% (105/726) of F3 patients progressed to cirrhosis, and over 15.9 mos, 2.8% (22/800) of F4 patients had liver-related events. Progression to cirrhosis was associated with greater area of Ishak 6 fibrosis and portal inflammation (Figure). Similar associations were observed in F4 patients, with hepatocellular ballooning and clinical events. In F3, a greater proportion of area of Ishak 1 fibrosis and steatosis were associated with a reduced risk of progression. In F4, area of steatosis was similarly protective, while proportion of Ishak Stage 1 Fibrosis over Ishak scored area trended towards protective. Conclusions: Liver histological evaluation using ML approach identified novel features associated with progression in NASH patients with advanced fibrosis. These data support the utility of ML approaches to evaluation of liver histology as endpoints in NASH clinical trials.
연관 검색어 추천
이 검색어로 많이 본 자료
활용도 높은 자료
